ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 922

Biologic DMARD Prescribing Patterns in Elderly Patients with Rheumatoid Arthritis

Britney Jones1, Imran Hassan2, Walter P. Maksymowych3 and Elaine Yacyshyn4, 1University of Alberta, Edmonton, AB, Canada, 2EPICORE Centre, University of Alberta, Edmonton, AB, Canada, 3Department of Rheumatology, University of Alberta, Edmonton, AB, Canada, 4Medicine, University of Alberta, Edmonton, AB, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Early Rheumatoid Arthritis, prescribing trends and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Healthcare Disparities in Rheumatology

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Rheumatoid arthritis is a chronic inflammatory process involving progressive destruction of joints.

Currently, 30% of rheumatoid arthritis (RA) patients are over the age of 65. As the population ages, shifts in epidemiology and disease patterns will require an appropriate response from the healthcare system. Elderly patients frequently have more active disease; however, inequalities in prescribing patterns may favor more aggressive treatment in younger patients. There are myriad different reasons why this may be the case; elderly patients tend to have a higher number of comorbidities, more medications, and a greater degree of frailty.

Elderly patients with RA benefit from tight disease control and use of biologic Disease Modifying Anti-rheumatic Drugs (boDMARDs) minimizes the need for other medications. There is a growing body of evidence suggesting that patient outcomes do not significantly decline with age. The reluctance to use boDMARDs in the elderly from concerns around side effects paradoxically means these patients may be exposed to much more deleterious drugs such as glucocorticoids, narcotics, and NSAIDs that may be less desirable in the elderly population.

This study identified differences in biologic prescribing patterns between young (<65 years old) and elderly (> 65 years old) patients with RA. Secondary outcomes examined demographic variation and disease activity between patient age groups.

Methods:

A retrospective cohort study of 1581 patients was conducted using information collected from the Rheumatoid Arthritis Pharmacovigilance Program and Outcomes Research in Therapeutics (RAPPORT) Database. This database encompasses an inception cohort of all RA patients in Northern Alberta starting treatment with biologics.

Fisher’s exact test was used to determine the age of RA patients at first boDMARD prescription using the cutoff of young (<65 years old) and elderly (> 65 years old).

Wilcoxon-Mann-Whitney test was used to stratify disease activity in different age groups using the Health Assessment Questionnaire (HAQ) and Disease Activity Score (DAS28).

Results:

A significantly larger proportion of young RA patients were prescribed boDMARDs compared with elderly RA patients (96.8% vs 90.0%; p = 0.006). Elderly patients prescribed boDMARDs had significantly higher HAQ (mean 1.69 +/- 0.66; p = 0.001) and DAS28 (mean 6.0 +/- 1.68; p = 0.002) scores compared to younger patients (mean 1.41 +/- 0.72 and mean 5.29 +/- 1.7, respectively)

There was no statistically significant difference in other demographic information including sex, ethnicity, and years of schooling.

Conclusion:

Despite current guidelines recommending early, aggressive disease control including the timely introduction of boDMARDs, this study suggests that a prescribing bias remains. Younger patients with lower levels of disease activity are more likely to receive biologic therapies than their elderly counterparts. While there was no statistically significant difference between the basic demographics of each cohort, patient’s level of frailty and comorbid conditions were not accounted for in this study.


Disclosure: B. Jones, None; I. Hassan, None; W. P. Maksymowych, None; E. Yacyshyn, None.

To cite this abstract in AMA style:

Jones B, Hassan I, Maksymowych WP, Yacyshyn E. Biologic DMARD Prescribing Patterns in Elderly Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/biologic-dmard-prescribing-patterns-in-elderly-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biologic-dmard-prescribing-patterns-in-elderly-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology